Drug recall · July 31, 2019
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension recall
Why: Superpotent Drug and Failed Stability Specifications: High out-of-specification results for the active ingredients, hydrocodone and chlorpheniramine, as well as high out-of-specification results for the preservatives.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension, (equivalent to 10 mg hydrocodone bitartrate and 8 mg chlorpheniramine maleate per 5 mL), 16 fl. oz. (473 mL) bottle, Rx only, Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 27808-086-02.
- Lots / codes
Lot#: 14079, Exp 10/2021
- Quantity
- 2,550 bottles
- Company
- Tris Pharma Inc., Monmouth Junction, NJ
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- July 11, 2019 · Voluntary: Firm initiated
- Classified
- July 24, 2019
- Reported
- July 31, 2019
- Ended
- November 2, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Chlorpheniramine / hydrocodone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.